These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1409406)

  • 1. An unexpected hydrolysis pH-rate profile, at pH values less than 7, of the labile imide, ICRF-187: (+)-1,2-bis-(3,5-dioxopiperazin-1-yl)propane.
    Sisco JM; Stella VJ
    Pharm Res; 1992 Sep; 9(9):1209-14. PubMed ID: 1409406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide?
    Sisco JM; Stella VJ
    Pharm Res; 1992 Aug; 9(8):1076-82. PubMed ID: 1409381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
    Diop NK; Vitellaro LK; Arnold P; Shang M; Marusak RA
    J Inorg Biochem; 2000 Feb; 78(3):209-16. PubMed ID: 10805177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
    Hasinoff BB
    J Pharm Sci; 1994 Jan; 83(1):64-7. PubMed ID: 8138912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
    Thomas C; Vile GF; Winterbourn CC
    Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.
    Hasinoff BB; Kala SV
    Agents Actions; 1993 May; 39(1-2):72-81. PubMed ID: 8285144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).
    Schroeder PE; Davidson JN; Hasinoff BB
    Drug Metab Dispos; 2002 Dec; 30(12):1431-5. PubMed ID: 12433815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
    Buss JL; Hasinoff BB
    Agents Actions; 1993 Sep; 40(1-2):86-95. PubMed ID: 8147274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
    Hasinoff BB; Reinders FX; Clark V
    Drug Metab Dispos; 1991; 19(1):74-80. PubMed ID: 1673425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.
    Burke TG; Lee TD; van Balgooy J; Doroshow JH
    J Pharm Sci; 1991 Apr; 80(4):338-40. PubMed ID: 1907658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
    Hasinoff BB
    Drug Metab Dispos; 1993; 21(5):883-8. PubMed ID: 7902252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical stability of the cardioprotective agent ICRF-187 in infusion fluids.
    Beijnen JH; van Gijn R
    J Parenter Sci Technol; 1993; 47(4):166-71. PubMed ID: 8410562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
    Hasinoff BB
    Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of an antimetastatic agent, (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF 159), on platelet behavior.
    Atherton A; Busfield D; Hellman K
    Cancer Res; 1975 Apr; 35(4):953-7. PubMed ID: 1116152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
    Vile GF; Winterbourn CC
    Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
    Gorbsky GJ
    Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
    el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
    Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of (+/-) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma.
    Atherton A
    Eur J Cancer (1965); 1975 Jun; 11(6):383-8. PubMed ID: 1174351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.